How do I set a price alert for IQV?

To set a IQV price alert on Stock Alarm Pro, navigate to the IQV quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for IQV?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for IQV. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for IQVIA?

Stock Alarm Pro supports over 125 trigger types for IQV: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about IQV price changes?

IQV alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for IQV alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for IQV and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

IQV Company Intelligence - Business Model, Drivers & Risks

IQVIA Holdings Inc.(IQV)

$256.20—

WatchlistAsk AI Chart

IQVIA Holdings Inc.(IQV)

NYSEAbout this data

$256.20—

WatchlistAsk AI Chart Studio

IQV(IQV)

IQV

IQVIA is the world's largest contract research organization (CRO) and healthcare data analytics provider, serving pharmaceutical and biotech clients across 100+ countries. The company combines clinical trial execution capabilities (Technology & Analytics Solutions segment, ~$8.5B revenue) with proprietary healthcare data assets covering 1+ billion patient records and real-world evidence platforms (R&DS segment, ~$7.8B revenue). Competitive moat derives from scale advantages in global site networks, longitudinal patient data assets, and embedded relationships with top 50 pharma companies.

HealthcareContract Research Organization & Healthcare Data Analyticsmoderate - R&DS segment has variable costs (clinical staff, site payments scale with trial activity) limiting margin expansion, while TAS segment exhibits high operating leverage with fixed costs in data infrastructure and software development. Consolidated operating margins have expanded from 12% to 14% as higher-margin TAS grows faster than R&DS. Incremental margins on revenue growth are 20-25%, constrained by labor-intensive clinical trial execution but supported by software/data scalability.

Business Overview

01Research & Development Solutions (R&DS): ~48% - clinical trial services, site management, patient recruitment, regulatory consulting across Phase I-IV trials

02Technology & Analytics Solutions (TAS): ~52% - proprietary healthcare databases, real-world evidence platforms, commercial analytics, IQVIA Orchestrated Customer Engagement (OCE) SaaS suite for pharma sales/marketing

03Contract Sales Organization (CSO) services embedded within TAS - field sales teams deployed for pharma clients

IQVIA monetizes through multi-year clinical trial contracts (typically 3-7 year duration with milestone-based billing) and subscription-based data/analytics licenses. R&DS operates on cost-plus or fixed-fee models with 15-20% operating margins, leveraging global investigator site networks across 100+ countries to execute trials at scale. TAS generates recurring revenue (60%+ of TAS is subscription-based) from proprietary longitudinal patient data covering pharmacy, medical, and hospital claims across 40+ countries, with 30%+ operating margins driven by software-like economics. Pricing power stems from switching costs (embedded workflows in pharma R&D processes), data network effects (more data improves predictive analytics), and regulatory expertise. The company benefits from pharma outsourcing trends (CRO penetration rising from 45% to 55%+ of R&D spend) and increasing demand for real-world evidence to support drug approvals and commercialization.

What Moves the Stock

R&DS backlog growth and book-to-bill ratio (backlog currently $28B+, representing 3.5+ years of revenue visibility)

TAS segment organic revenue growth and subscription renewal rates (target 6-8% organic growth)

Pharma R&D spending trends and clinical trial starts (particularly large Phase III oncology and rare disease trials)

Operating margin expansion trajectory toward 16-17% medium-term target

Large contract wins with top 20 pharma clients (Pfizer, Novartis, Roche, etc.) and biotech funding environment

Real-world evidence platform adoption and regulatory acceptance (FDA/EMA guidelines on RWE for drug approvals)

Watch on Earnings

R&DS contracted backlog and net new business (book-to-bill ratio, target >1.1x)TAS organic constant-currency revenue growth and subscription ARRAdjusted EBITDA margin and free cash flow conversion (target >90% of adjusted net income)Days sales outstanding (DSO) and working capital efficiencyFull-year revenue and EPS guidance revisions

Risk Factors

Regulatory changes to clinical trial requirements (e.g., decentralized trials, AI-enabled trial designs) could disrupt traditional site-based CRO model and require significant technology investments

Data privacy regulations (GDPR, HIPAA expansions) increasing compliance costs and potentially limiting access to patient-level data that underpins TAS competitive advantage

Pharma industry consolidation reducing number of independent clients and increasing buyer negotiating power (top 10 pharma represent 40%+ of revenue)

Emergence of technology-native competitors (e.g., clinical trial platforms like Science 37, AI drug discovery firms) unbundling traditional CRO services

Intense competition from other large CROs (LabCorp Drug Development, Syneos Health, PPD/Thermo Fisher) and niche specialists in oncology/rare disease trials, pressuring pricing and win rates

Large pharma clients increasingly insourcing clinical operations and building internal data analytics capabilities, particularly for early-stage trials

Technology platforms (Veeva CRM, Salesforce Health Cloud) competing with IQVIA OCE suite for pharma commercial analytics spend

Elevated leverage at 2.5x net debt/EBITDA (vs. 1.5-2.0x peer average) limits financial flexibility and M&A capacity, with $13.5B gross debt requiring $500M+ annual interest payments

Current ratio of 0.75x indicates working capital pressure, though mitigated by strong operating cash flow generation ($2.7B annually) and asset-light model

Pension obligations and deferred tax liabilities from historical acquisitions (Quintiles-IMS merger) create off-balance-sheet risks

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - Revenue is 80%+ driven by pharmaceutical R&D budgets which are relatively stable through economic cycles (drug development timelines are 10+ years, creating inertia). However, biotech funding is cyclical and sensitive to venture capital availability and IPO markets. During recessions, small/mid-cap biotech clients (20-25% of revenue) face funding pressures, while large pharma (60%+ of revenue) maintains R&D spend. TAS segment is more defensive with subscription revenue, while R&DS has 12-18 month lag between economic stress and trial cancellations.

Interest Rates

Rising rates create headwinds through two channels: (1) biotech funding environment deteriorates as venture capital and IPO markets contract, reducing trial starts from small/mid-cap clients, and (2) higher discount rates compress valuation multiples for high-growth healthcare services (stock trades at 12-14x forward EBITDA, sensitive to 50-100bp multiple compression when 10-year yields rise 100bp+). Operationally, IQVIA carries $13.5B debt (2.5x net leverage) with ~60% fixed-rate, so 100bp rate increase impacts interest expense by $20-25M annually. Positive offset: higher rates don't significantly impact pharma client budgets as large pharma has strong balance sheets.

Credit

Moderate exposure to biotech credit conditions. Small/mid-cap biotech clients represent 20-25% of revenue and are sensitive to venture debt availability and equity financing markets. IQVIA mitigates risk through milestone-based billing and upfront payments (typically 20-30% of contract value), but biotech bankruptcies can lead to contract cancellations and bad debt write-offs. Large pharma clients (investment-grade rated) represent minimal credit risk. Company maintains strong working capital management with DSO of 50-55 days.

Live Conditions

S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth-at-reasonable-price (GARP) - Investors seek exposure to secular pharma outsourcing trends (CRO penetration rising from 45% to 60%+ over next decade) and healthcare data monetization, with 5-7% organic revenue growth and 15-20% EPS growth from margin expansion and buybacks. Stock appeals to healthcare specialists and quality-focused funds given high barriers to entry (proprietary data, regulatory expertise, global scale). Recent 25% drawdown has attracted value-oriented investors given 12x forward EBITDA (vs. 15x historical average) and 7%+ FCF yield. Dividend investors less attracted (no dividend, 100% FCF allocated to debt paydown and opportunistic buybacks).

moderate - Beta of 1.0-1.1 reflects correlation with broader healthcare sector and biotech funding cycles. Stock experiences 15-20% drawdowns during biotech bear markets (2022: -30%, 2016: -25%) but outperforms in stable growth environments. Quarterly earnings volatility is low given revenue visibility from backlog, but stock is sensitive to guidance revisions and large contract win/loss announcements. Institutional ownership at 90%+ reduces retail-driven volatility.

Key Metrics to Watch

Biotech IPO and venture funding volumes (proxy for small/mid-cap client health and future trial starts)

FDA and EMA new drug approvals (NDA/BLA submissions drive demand for Phase III/IV trials and real-world evidence studies)

Pharmaceutical R&D spending as % of revenue for top 20 pharma (industry target 15-20%, drives outsourcing budgets)

Clinical trial starts globally (ClinicalTrials.gov registrations, particularly Phase III oncology and rare disease)

IQVIA contracted backlog growth rate and book-to-bill ratio (leading indicator of revenue 12-18 months forward)

TAS subscription renewal rates and net revenue retention (indicator of data platform stickiness)

Nasdaq Biotechnology Index (NBI) performance as proxy for biotech funding environment

pharma biotech healthcare clinical trial debt

Explore More

Healthcare Stocks

More Healthcare stocks

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers